#### AGIOS PHARMACEUTICALS INC

Form 4

September 12, 2014

### FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** Number:

3235-0287

2005

0.5

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, Expires:

Estimated average burden hours per

**OMB APPROVAL** 

Form 4 or Form 5 obligations

Section 16.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

response...

See Instruction

may continue.

1(b).

(Print or Type Responses)

1. Name and Addr THIRD ROCK	•	_	2. Issuer Name <b>and</b> Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer			
			AGIOS PHARMACEUTICALS INC [AGIO]	(Check all applicable)			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	DirectorX10% Owner Officer (give title Other (specify			
29 NEWBURY STREET, 3RD			09/11/2014	below) below)			
FLOOR			33,23,24,2				
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check			
			Filed(Month/Day/Year)	Applicable Line) Form filed by One Reporting Person			
BOSTON, MA 02116				_X_ Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acq	uired, Disposed of, or Beneficially Own			

(City)	(State) (	Zip) Table	e I - Non-D	erivative Se	curitie	es Acqu	iired, Disposed of	f, or Beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securitie n(A) or Disp (Instr. 3, 4)	osed o		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/11/2014		J <u>(1)</u>	825,000	D	\$ 0	3,070,090	D (2)	
Common Stock	09/11/2014		J <u>(3)</u>	60,567	A	\$0	60,567	D (4)	
Common Stock	09/11/2014		J <u>(5)</u>	60,567	D	\$0	0	D (4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form

#### Edgar Filing: AGIOS PHARMACEUTICALS INC - Form 4

## displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. onNumber of Derivative		ate	Secur	ant of rlying rities	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene
	Derivative Security				Securities Acquired			(Instr	. 3 and 4)		Owne Follo
	Ť				(A) or						Repo
					Disposed of (D)						Trans (Instr
					(Instr. 3, 4, and 5)						
					4, and 3)				<b>A4</b>		
						Date Exercisable	Expiration Date	Title	Amount or Number of		
				Code V	(A) (D)				Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
Trepozonia o minor i minor, i minorio	Director	10% Owner	Officer	Other		
THIRD ROCK VENTURES LP 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116		X				
Third Rock Ventures GP, L.P. 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116		X				
TRV GP, LLC 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116		X				

## **Signatures**

/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P., general partner of Third Rock Ventures, L.P.				
**Signature of Reporting Person	Date			
/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P.				
**Signature of Reporting Person	Date			
/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC	09/12/2014			
***Signature of Reporting Person	Date			

Reporting Owners 2

#### Edgar Filing: AGIOS PHARMACEUTICALS INC - Form 4

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Distribution of shares in kind by Third Rock Ventures, L.P. ("TRV") on a pro rata basis to its partners.
- The shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC") and , as such, each of TRV GP and TRV GP LLC exercises shared voting and investment power over the shares held of record by TRV. Each Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any.
- (3) TRV GP received shares distributed in kind by TRV on a pro rata basis to its partners.
  - The shares are directly held by TRV GP. As such, TRV GP LLC exercises voting and investment power over the shares held of record by
- (4) TRV GP. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any.
- (5) Distribution of shares in kind by TRV GP on a pro rata basis to its partners.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.